

Peptide-based probes for protein N-Methyltransferases Zhang, Y.

Citation

Zhang, Y. (2022, June 2). *Peptide-based probes for protein N-Methyltransferases*. Retrieved from https://hdl.handle.net/1887/3307258

Version:	Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/3307258

Note: To cite this publication please use the final published version (if applicable).

A Direct Assay for Measuring Activity and Inhibition of Coactivator Associated Arginine Methyltransferase 1



Accepted by Biochemistry

Abstract

Coactivator-associated arginine methyltransferase 1 (CARM1) is a member of the family of protein arginine methyltransferases. CARM1 catalyzes methyl group transfer from the cofactor S-adenosyl-L-methionine (AdoMet) to both histone and non-histone protein substrates. CARM1 is involved in a range of cellular processes, mainly involving RNA transcription and gene regulation. As the aberrant expression of CARM1 has been linked to tumorigenesis, the enzyme is a potential therapeutic target, leading to the development of inhibitors and tool compounds engaging with CARM1. In order to evaluate the effects of these compounds on the activity of CARM1, sensitive and specific analytical methods are needed. While different methods are currently available to assess the activity of methyltransferases, these assays mainly focus on either the measurement of the cofactor product S-adenosyl-L-homocysteine (AdoHcy) or employ radioactive or expensive reagents, each with their own advantages and limitations. To complement the tools currently available for analysis of CARM1 activity, we here describe the development of a convenient assay employing peptide substrates derived from poly(A)-binding protein 1 (PABP1). This operationally straightforward LC-MS/MS based approach allows for the direct detection of substrate methylation with minimal workup. The method was validated and its value in characterizing CARM1 activity and inhibition demonstrated through a comparative analysis involving a set of established small molecule and peptide-based CARM1 inhibitors.

Introduction

Cofactor-associated arginine methyltransferase 1 (CARM1) is a member of the family of protein arginine N-methyltransferases (PRMTs), responsible for the methylation of arginine residues in a variety of nuclear protein substrates, including histone tails, RNA binding proteins and splicing factors.^{1, 2} Arginine methylation in histones and other nuclear proteins plays an important role in regulating a range of cellular processes, including gene regulation, signal transduction, RNA processing, and DNA repair.^{3, 4} PRMTs can be classified into three types based on their primary product formation: type I PRMTs result in both ω -N^G-monomethyl arginine (MMA) and asymmetrically ω -N^G,N^G dimethylated arginine (aDMA), type II PRMTs catalyze the formation of MMA and symmetrical ω -N^G,N^G –dimethylarginine (sDMA), while type III PRMTs exclusively form MMA.^{5, 6} As a type I PRMT, CARM1 catalyzes the transfer of the methyl group from S-adenosyl-L-methionine (AdoMet) to first generate MMA followed directly by a second methylation step resulting in the formation of aDMA (Figure 1). The methyl group transfer from AdoMet to the protein substrate generates the by-product S-adenosyl-L-homocysteine (AdoHcy), which in turn can inhibit CARM1 as a feedback inhibitor.⁷



Figure 1. CARM1 catalyzes the methylation of arginine residues in substrate proteins and peptides to generate monomethyl arginine (MMA) and asymmetric dimethyl arginine (aDMA).

The aberrant expression of CARM1 has been linked to a variety of disease states, most prominently in the field of cancer. CARM1 overexpression is linked to ovarian, colorectal, prostate, and lung cancers.⁸⁻¹⁰ In addition, CARM1 was found to promote cell proliferation of ER α -positive breast cancer cells.¹¹ These findings

have led to interest in CARM1 as a potential therapeutic target for the treatment of cancer. To facilitate the development of inhibitors of CARM1, reliable, specific, and rapid analytical methods for characterizing its activity are vital. Generally, analytical methods for the detection of methyltransferase activity focus on the detection of enzymatic by-product AdoHcy. Several high-throughput assays are available for the detection of AdoHcy, either directly by chromatographic means,¹² or indirectly, using enzyme-coupled assays in which AdoHcy formation leads to a luminescent or fluorescent signal.^{13,14} Using such an approach, we recently investigated the use of a commercially available assay kit (MTase Glo) for the purposes of studying CARM1 activity but were not able to achieve consistent results (data not shown). We attribute this to the previously noted high background signal encountered with this method owing to the auto-methylating ability of CARM1 at its own arginine residue R551.¹⁵ These findings suggested to us that methods relying on the detection of AdoHcy formation are not optimal for the quantification of CARM1 activity. For this reason, we were inspired to develop of an alternative assay focused on the direct detection of the methylated products formed by CARM1.

Substrate methylation can be quantified using existing methods for example through the use of radio-labeled ³H-AdoMet¹⁶ to measure direct methyl group addition or indirectly through the use of antibodies developed against specific methylated epitopes.¹⁷ There are, however, several disadvantages to these assays. While compatible with high-throughput screening (HTS), radiometric approaches require strict operating conditions, radio-protected equipment, and specific laboratory setups. In comparison, while antibody-based ELISA assays avoid the use of radioactivity, they are expensive and involve complex experimental protocols that are not suitable for high-throughput screening. To address these shortcomings, we here describe the development of a rapid, straightforward, and sensitive CARM1-specific assay. Specifically, our method relies upon the direct detection of the dimethylated products formed when substrate peptides derived from poly(A)-binding protein 1 (PABP1) are incubated with CARM1 and AdoMet. Using an LC-MS based approach, the enzymatic products are readily detected via multiple reaction monitoring (MRM) and quantified by comparison to a hexadeuteromethylated species serving as internal standard. MRM is a technique widely used in quantitative proteomics because of its high selectivity using two levels of mass detection, high sensitivity, and wide dynamic range.¹⁸ We further demonstrate the suitability of this rapid and direct analytical method in characterizing CARM1 inhibition by evaluating a number of established CARM1 inhibitors. Notably, the results obtained with our assay were found to compare well with those obtained when using a more operationally complex antibody-based chemiluminescent method. The analytical method here reported provides high selectivity and sensitivity in the characterization of CARM1 activity and offers a simplified approach to screening for inhibitors of CARM1.

Result and Discussion

Analytical method development

To achieve a rapid and direct analytical method for the quantification of CARM1 activity, we have developed an LC-MS method using multiple reaction monitoring (MRM) analysis and optimized to obtain maximal detection sensitivity and accuracy. In search of a peptide substrate suitable for use in an LC-MS based activity assay for CARM1, we initially focused our attention on peptides derived from histone H3. Tail peptides from H3 are well-characterized substrates of CARM1, with preferential methylation occurring at arginine residue H3R17.^{19, 20-22} To assess the suitability of H3 peptides with the envisioned LC-MS detection method, we first synthesized H3¹⁶⁻³⁰, incorporating an asymmetrically dimethylated arginine residue at arginine 17. Subsequent Analysis of the H3¹⁶⁻³⁰ R¹⁷aDMA peptide by LC-MS was found to produce a distribution of m/z values rather than a major single precursor ion owing to the presence of other arginine and lysine residues in the sequence. This in turn led to a significant reduction in signal as even when selecting for the major precursor ion, approximately 75% of total signal was lost. No significant improvement was observed when using buffers at different pH in an attempt to tune the charge distribution of the peptide (data not shown). We therefore opted to evaluate different substrate peptides not based on H3 but rather derived from poly(A)-binding protein 1 (PABP1), a protein known to be efficiently methylated by CARM1 at arginine residues 455 and 460.^{23,24} Notably, the PABP1 sequences PABP1⁴⁴⁷⁻⁴⁵⁹ and PABP1⁴⁵⁶⁻⁴⁶⁶ do not include any additional positively charged residues other than the arginine residues R⁴⁵⁵ and R⁴⁶⁰, respectively. To this end, PAPB1⁴⁴⁷⁻⁴⁵⁹ R⁴⁵⁵aDMA and PAPB1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰aDMA were synthesized and analyzed by LC-MS. Based on peak shape and signal intensity, PAPB1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰aDMA was identified as the preferred analyte and used for optimization. In contrast to the histone H3 sequence, mass analysis of this PABP1 sequence yielded a single major peak (m/z = 620.850, corresponding to $[M+2H]^{2+}$) which was subsequently selected as the precursor ion for further MRM optimization (see Figure. S1 and S2 in the Appendix III).

During the optimization of the MRM method, we examined the influence of mobile phase composition and pH, column temperature, and flow rate on the elution profile of the PAPB1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰aDMA standard. Initial attempts employed isocratic elution with a mobile phase consisting of 25% acetonitrile containing 20 mM NH₄Ac (pH 7, flow rate is 0.5 mL·min⁻¹ at 30 °C) and 20 mM NH₄Ac (pH 9, flow rate is 0.5 mL·min⁻¹ at 30 °C), respectively. These conditions yielded a broad saw-like peak for the peptidic analyte. When the mobile phase was changed to

25% acetonitrile containing 0.1% formic acid (pH 2), a smooth peak resulted but still gave a broad signal with significant peak tailing. To improve peak shape, we subsequently evaluated gradients of acetonitrile in aqueous formic acid (0.1%). This led to an optimized method employing a gradient moving from 20% to 92% acetonitrile in aqueous formic acid (0.1%) (pH 2) which reliably gave a sharp and symmetrical peak for PAPB1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰aDMA. Variation of the slope of the gradient (between 6 and 20 minutes) did not significantly affect the peak shape, allowing for a convenient run time of 6 minutes. Subsequently, we examined the column temperature (up to 60 °C) and flow rate (0.5 and 1 mL·min⁻¹), but this provided no significant improvement. The final conditions were therefore set on a method with a run time of 6 minutes and a gradient of 20% to 92% acetonitrile in water containing 0.1% formic acid with a flow rate of 0.5 mL·min⁻¹ at 30 °C. The MRM parameters generated for the PAPB1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰aDMA through an automated methodology of the mass spectrometer were incorporated in the LC-MS method.

Internal standards. As an internal standard we prepared the hexadeuterated form of the analyte, PAPB1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰-d₆-aDMA. In doing so, any changes in the analyte signal resulting from variation in the workup or the analytical method (e.g. due to matrix effects, ion suppression, precipitation, or non-specific binding) can be corrected for. Isotopically labeled compounds have the same chromatographic behavior and show the same ionization and fragmentation pattern as their non-labeled counterparts, but can be separated based on their mass difference. The synthesis of PAPB1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰-d₆-aDMA was conducted as for the non-deuterated species with the exception that a hexadeuterated aDMA building block was required which was prepared following protocols previously reported by our group.^{25,26}

Optimization of the Enzymatic activity assay. The conditions of the enzymatic activity assay were optimized with respect to buffer composition, reaction time, and work-up. The optimized buffer consists of 20 mM Tris buffer (pH 8) containing 50 mM NaCl, 1 mM EDTA, 3 mM MgCl₂, 0.1 mg/ml BSA, and 1mM DTT. The addition of DTT was vital for avoiding disulfide bond formation and the addition of BSA was found necessary to keep CARM1 in its active form by blocking aggregation and reducing unspecific binding of the CARM1 to the well plate. Sample work-up consisted of quenching the enzyme reaction by addition of 0.1% formic acid solution (known to be compatible with the MS conditions of the assay²⁷) and addition of the internal standard.

In order to maximize the signal for the enzymatic reaction, a screen was performed to establish both the optimal concentration of enzyme and incubation time. For CARM1, the half maximal effective concentration (EC_{50}) determination was performed using CARM1 enzyme at concentrations of 0.875, 1.75, 3.5, 7, 14,

28, 56 and 112 ng/µL. Substrates were fixed at 100 µM PAPB1 $^{456\text{-}466}$ and 10 µM AdoMet and samples were taken every 15 minutes for 2 hours. The CARM1 EC_{50} value was thus established to be 11.68 ± 0.33 ng/µL (see Figure. S3 in the Appendix III), which is in good agreement with the final concentration of CARM1 used in the commercially available chemiluminescent assay kit (BPS Bioscience, Catalog #52041L; CARM1 concentration is 10 ng/ µL or 200 ng per reaction). For the determination of the $K_{\rm M}$ value of $\text{PABP1}^{456\text{--}466},$ formation of the methylated product was analyzed in the presence of a fixed concentration of 100 µM AdoMet and PABP1⁴⁵⁶⁻⁴⁶⁶ applied over a concentration range of 0.05 μ M to 100 μ M. For the determination of the K_M value of AdoMet, the methylated substrate was analyzed in the presence of a fixed concentration of 100 µM PABP1 and AdoMet concentrations ranging from 0.05 μ M to 100 μ M. The K_M values thus obtained were 12.03 \pm 2.28 μ M for PABP1⁴⁵⁶⁻⁴⁶⁶ and 5.46 \pm 0.01 μ M for AdoMet (see Figure. S3 in the Appendix III). Based on these findings, when performing the subsequent inhibition studies CARM1 was used at a concentration of 11.68 ng/µL while the substrate concentrations were fixed at 12 µM PABP1 and 10 µM AdoMet.

Inhibitor studies. We next applied the assay in assessing the inhibition of CARM1 by a number of known inhibitors of varying potencies including AdoHcy (1), MS023 (2), MS049 (3), TP064 (4), and a series of recently reported peptidomimetic CARM1 inhibitors (5-9) (Figure. 2).^{28, 29-32} For the purpose of generating IC_{50} curves for these inhibitors, concentration ranges were set according to previously reported IC₅₀ values. The inhibitors were first incubated with CARM1 for 15 minutes at room temperature before the enzyme reaction was initiated by addition of the AdoMet/PABP1⁴⁵⁶⁻⁴⁶⁶ substrate mixture. On the basis of the residual CARM1 activity measured, inhibition curves were generated and the IC₅₀ values determined (Table 1). In order to evaluate the suitability of the method for the determination of CARM1 inhibition, the IC₅₀ values were compared with those obtained using a commercially available chemiluminescent ELISA kit. The conditions used with this kit are comparable to those used here in terms of enzyme concentrations, but a slightly lower AdoMet concentration is applied in the kit (1 µM versus 10 µM). In addition, the peptide substrate and detection method employed in the ELISA kit are inherently different. The kit employs a histone H3 derived peptide that is covalently linked to the bottom of the well plate and as such no substrate concentration is given. Product formation in turn is detected using specific antibodies that recognize aDMA formation at arginine residue H3R17.

The results of the inhibitor screen are summarized in Table 1 and show that the potency trend for the IC_{50} values obtained with the MRM LC-MS assay corresponds very well with that obtained with the ELISA based method (Table 1). The absolute IC_{50} values measured via the MRM LC-MS assay were found to be generally 2-4 times higher than those obtained via the ELISA assay, an effect we ascribe to the

differences in assay conditions and methodology. The most notable differences between the MRM LC-MS and ELISA assays lie in the AdoMet concentrations and peptide substrates used. The MRM LC-MS method here reported uses a 10-fold higher concentration of AdoMet which likely impacts the IC₅₀ values measured. Furthermore, MRM LC-MS assay detects the CARM1 catalyzed methylation of a PAPB1 derived substrate while the ELISA method employs an H3 based peptide substrate. Notably, the published _{KM} value of CARM1 for such H3 substrates (112 μ M)³³ is 10-fold higher than that of PABP1 based substrates (K_M, = 12 μ M, this work). In the context of inhibition assays, the higher affinity of CARM1 for PABP1 based substrates versus those derived from H3 is also likely to impact the relative IC₅₀ values measured for competitive inhibitors.



Figure 2. Overview of the chemical structures of reported small molecule CARM1 inhibitors AdoHcy (1), MS023 (2), MS049 (3) and TP064 (4) and peptidomimetic inhibitors $H3^{10-25}R^{17*}$ (5), $H3^{14-21}R^{17*}$ (6), $H3^{15-20}R^{17*}$ (7), $H3^{16-19}R^{17*}$ (8), and PABP1⁴⁵⁶⁻⁴⁶⁶R^{460*} (9).

Inhibitor		CARM1 IC ₅₀ values (µM) ^a			
Number	Compound name	MRM LC-MS Assay	ELISA Assay		
1	AdoHcy	0.873 ± 0.339	$0.276 \pm 0.074 \ (ref \ 27)$		
2	MS023	0.327 ± 0.034	0.101 ± 0.011 (this work)		
3	MS049	0.082 ± 0.008	0.028 ± 0.003 (this work)		
4	TP064	0.162 ± 0.010	0.037 ± 0.008 (this work)		
5	H3 ¹⁰⁻²⁵ R ^{17*}	0.770 ± 0.098	$0.290 \pm 0.021 \ (ref \ 20)$		
6	H3 ¹⁴⁻²¹ R ^{17*}	0.403 ± 0.028	$0.287 \pm 0.048 \ (ref \ 20)$		
7	H3 ¹⁵⁻²⁰ R ^{17*}	0.617 ± 0.057	$0.143 \pm 0.020 \; (ref\; 20)$		
8	H3 ¹⁶⁻¹⁹ R ^{17*}	1.456 ± 0.021	$0.346 \pm 0.044 \text{ (ref 20)}$		
9	PABP1456-466 R460*	0.212 ± 0.025	$0.090 \pm 0.016 \text{ (ref 27)}$		

Table 1. Inhibition data for compounds 1-9 against CARM1 tested by MRM and ELISA assay

^aIC₅₀ values reported in μ M from duplicate data obtained from a minimum of 7 different concentrations ± standard error of the mean (s.e.m.). Full inhibition curves are provided in the Appendix III.

Conclusion

We here describe the development of a direct, specific, and convenient analytical method for measuring the activity of CARM1. The LC-MS based method applies multiple reaction monitoring (MRM) for the detection and quantification of a methylated peptide substrate (PAPB1⁴⁵⁶⁻⁴⁶⁶ R⁴⁶⁰aDMA). The assay presents a significant simplification over existing ELISA and radiometric methods while benefitting from high sensitivity and convenient sample preparation. Compared with the widely used radiolabeled AdoMet assay, the MRM LC-MS assay is not restricted by specialized operational and laboratory conditions. We have also demonstrated the application of the MRM LC-MS method in assaying the inhibitory activity of a selection of known CARM1 inhibitors by generating CARM1 inhibition curves. The IC₅₀ values obtained were found to be comparable with published values and with values obtained with the commercially available ELISA kit. Considering the growing body of evidence for CARM1 as a therapeutic target, the MRM LC-MS assay here described represents a valuable addition to the tools available for the identification of CARM1 inhibitors. Furthermore, the 6-minute run time of the MRM LC-MS assay allows for the convenient assessment of focused libraries number in the tens-to-hundreds of compounds. While HTS campaigns for CARM1 inhibitor identification typically rely on alternative methods such as radiometric detection, the CARM1-specificity of the MRM LC-MS assay makes

it very well suited for hit validation purposes. In addition, the approach here described should be widely applicable in the development of assays for other methyltransferases provided that compatible substrates are available.

Experimental Procedures

Building block Synthesis. The Fmoc-d₆-aDMA(Pbf)-OH building block was synthesized from commercially available Fmoc-Orn(Boc)-OH 9 following the synthetic route for Fmoc-aDMA(Pbf)-OH as previously described (Scheme 1)²⁵. Briefly, compound 9 was transformed into allyl ester 10 catalyzed with allyl alcohol, HOBt, DMAP and DCC in THF. Subsequently, allyl ester 10 was treated with TFA/DCM (2:1) to remove the Boc group and reacted with 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl isothiocyanate (Pbf-NCS) to form Pbf-protected thiourea 11. Finally, compound 11 was reacted with dimethyl-d₆-amine hydrochloride in the presence of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDCI) to form the intermediate guanidine species which was treated directly with tetrakis(triphenylphosphine) palladium(0) to form Pbf-protected Fmoc building block 12 which used for solid phase peptide synthesis.



Scheme 1. Synthesis of Fmoc-d6-aDMA. a. allyl alcohol, HOBt, DMAP, DCC, THF, overnight, (yield 62%); b. TFA/DCM(2:1),1h; c. Pbf-NCS in DCM (0.1 M), 2h, (yield 60%); d. EDCI, bis(methyl-d3)amine hydrochloride, DCM, overnight; e. Pd(PPh₃)₄, N-methylaniline, N₂, overnight, (yield 85% over 2 steps).

(E) - N 2 - (((9 H - fluoren - 9 - yl) methoxy) carbonyl) - N °, N ° - bis (methyl-d3)-N°'-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)arginine (12)

To a solution of compound 3 (610 mg, 0.86 mmol) in DCM (30 mL), 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (269 mg, 1.73 mmol) and bis(methyl-d₃)amine hydrochloride (151 mg, 1.73 mmol) were added. The mixture was stirred overnight at room temperature. The mixture was diluted with DCM (50 mL), washed with 10% citric acid (2 x 20 mL) and saturated sodium bicarbonate (2 x 20 mL) and dried over sodium sulfate. The organic solvent was removed and the residue was redissolved in THF (40 mL). The mixture was treated with N-methylaniline (238 μ L, 2.31 mmol), followed by addition of tetrakis(triphenylphosphine) palladium(0) (41.4 mg, 0.04 mmol). The mixture was protected from light and stirred under nitrogen at room temperature. After TLC indicated completion of the allyl ester removal, the solvent was removed under reduced pressure and purified by column chromatography (2% methanol in DCM) to yield compound 4 (500 mg, 85%) as a white foam. HRMS (m/z): $[M+H]^+$ calculated for $C_{36}H_{39}D_6N_4O_7S^+$, 683.3385, found 683.3345.¹H NMR (500 MHz, CDCl₃) δ 8.17 (s, 1H), 7.64 (d, J = 7.6 Hz, 2H), 7.48 (dd, J = 7.6, 4.5 Hz, 2H), 7.28 (m, J = 7.3 Hz, 2H), 7.19 – 7.15 (m, 2H), 6.00 (d, J = 7.7 Hz, 1H), 4.22 (m, J = 7.1, 3.1 Hz, 2H), 4.15 (d, J = 6.4 Hz, 1H), 4.08 (t, J = 7.3 Hz, 1H), 3.30 – 3.07 (m, 2H), 2.84 (s, 2H), 2.38 (s, 3H), 2.32 (s, 3H), 1.98 (s, 3H), 1.81 – 1.48 (m, 4H), 1.35 (s, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 174.33, 161.58, 161.28, 160.98, 160.79, 160.67, 156.89, 155.62, 143.84, 143.73, 141.36, 139.87, 135.23, 135.18, 135.13, 134.10, 130.67, 129.01, 128.25, 128.21, 128.17, 127.90, 127.27, 125.89, 125.30, 120.09, 118.72, 87.59, 77.42, 77.16, 76.91, 67.56, 53.36, 47.10, 45.05, 42.92, 29.50, 28.53, 24.96, 19.42, 18.07, 12.49.

CARM1 Cloning, Expression, and Purification. The mus musculus CARM1 (mmCARM1) gene sequence corresponding to the PRMT core (residues 130 to 497, mmCARM1₁₃₀₋₄₉₇) were amplified by PCR from the original GST-CARM1 construct.¹⁹ The sequences were cloned in the pDONR207[™] (Invitrogen) vector using a BP reaction (Gateway[®] Cloning, Life Technologies). The positive clones were confirmed by sequencing (GATC). The sequences were subcloned in a pDEST20[™] vector using an LR reaction. The resulting recombinant protein is harboring an amino-terminal glutathione S-transferase (GST) tag followed by a Tobacco etch virus (TEV) protease cleavage site. DH10Bac competent cells containing the baculovirus genome were transformed with the pDEST20[™]-CARM1 plasmids and plated onto LB agar media containing 15 mg.mL⁻¹ tetracycline, 7 mg.mL⁻¹ gentamicin, 50 mg.mL⁻¹ kanamycin, 25 mg.mL⁻¹ X-Gal and 40 mg.mL⁻¹ IPTG. Bacmid DNA purified from recombinationpositive white colonies was transfected into Sf9 cells using the Lipofectin reagent (Invitrogen). Viruses were harvested 10 days after transfection. Sf9 cells were grown at 300 K in suspension culture in Grace medium (Gibco) using Bellco spinner flasks. 1 L of sf9 cell culture (at 0.8 x 10⁶ cells.mL⁻¹) was infected with recombinant GST-mmCARM1 virus with an infection multiplicity of 1. Cells were harvested 48 h post-infection. Cell lysis was performed by sonication in 50 mL buffer A [50 mM Tris-HCl pH 8.0, 250 mM NaCl, 5% glycerol, 5 mM TCEP, 0.01% NP40 and antiproteases (Roche, Complete[™], EDTA-free)] and cellular debris were sedimented by centrifugation of the lysate at 40,000 x g for 30 min. The supernatant was incubated overnight at 277 K with 2 mL glutathione Sepharose resin (GE Healthcare). After a short centrifugation, the supernatants were discarded, and the beads were poured in an Econo-column (Bio-Rad). After two washing steps with 10 mL buffer A, 2 mL buffer A supplemented with in-house produced TEV protease was applied to the columns and digestion was performed for 4 hours at 303 K with gentle mixing.

The digest was concentrated with an Amicon Ultra 10K (Milipore), loaded on a gelfiltration column (HiLoad 16/60 Superdex S200, GE Healthcare) and eluted at 1 mL.min⁻¹ with buffer B [20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM TCEP] using an ÄKTA Purifier device (GE Healthcare). Fractions containing mmCARM1₁₃₀₋₄₉₇ were pooled and concentrated to 7.75 mg.mL⁻¹.

Peptide Synthesis. The PABP1⁴⁵⁶⁻⁴⁶⁶ peptides (Figure 3) used in the study were prepared via solid phase peptide synthesis (SPPS) using a CEM Liberty Blue microwave-assisted peptide synthesizer. The Fmoc protected Rink amide AM resin (0.1 mmol) was first swollen in 10 mL of a 1:1 mixture of DMF/DCM for 5 min, drained, and treated with 20 vol.% piperidine (10 mL) in DMF for 65 seconds at 90°C, drained and washed with DMF (3 x 5 mL). The resin was then treated with a solution of Fmoc-Met-OH (0.2 M, 2.5 mL, 5 eq), DIC (1 M, 1 mL, 10 eq) and Oxyma (1 M, 0.5 mL, 5 eq) in DMF (4 mL) at 76°C for 15 s before the temperature was increased to 90°C for an additional 110 s before being drained. To achieve maximal yield, each amino acid was double coupled according to the previous cycle. Following Fmoc removal with 20 vol.% piperidine (10 mL) in DMF for 65 seconds at 90°C, the resin was drained and washed with DMF (3 x 5 mL) after which the subsequent amino acids were coupled. All Fmoc amino acids were obtained commercially with the exception of Fmoc-d₆-aDMA(Pbf)-OH which was prepared as described in the supporting information. After coupling and deprotection of the final amino acid, the N-terminus was acetylated on resin using acetic anhydride (0.5 mL) and DiPEA (0.85 mL) in DMF (10 mL) for 120 s at 65°C. Then the resin was washed three times with DMF (10 mL). The final peptides were cleaved from the resin using a mixture of TFA/water/TIPS (95:2.5:2.5) under shaking for 2 hours at room temperature. The resin was filtered over cotton and washed with TFA (2 x 0.5 mL). The crude peptides were precipitated in a mixture of MTBE/Hexane (1:1) and pelleted by centrifugation (5 min at 4500 rpm). The pellet was then washed twice with MTBE/Hexane (1:1) (50 mL), centrifuged (5 min at 4500 rpm), and dried under a nitrogen flow. The crude peptides were purified by prep-HPLC and characterized by LC-MS and HRMS. The final yield of the peptides ranges from 30-40%.

Enzymatic Activity Assay. Enzyme activity assays were performed with CARM1 (11.68 ng/µL or 200 nM) in 20 mM Tris buffer (pH 8) containing 50 mM Tris NaCl, 1 mM EDTA, 3 mM MgCl₂, 0.1 mg/ml BSA and 1 mM dithiothreitol (DTT). The enzyme mixture (20 µL) was added to the substrate mixture (20 µL) containing the PABP1⁴⁵⁶⁻⁴⁶⁶ substrate peptide and AdoMet (final concentrations of 12 µM and 10 µM respectively) followed by incubation for two hours at room temperature. The reaction was subsequently quenched by addition of 30 µL of the reaction mixture to 10 µL of a 0.1 % formic acid solution (pH 2). After addition of the deuterated internal standard in water (100 nM, 40 µL) and mixing for 2 minutes, the samples were centrifuged for 5 minutes at 3000 rpm. 60 µL of the supernatant was

transferred to a new 96-well plate and analyzed.



Figure 3. Structures of the PABP1⁴⁵⁶⁻⁴⁶⁶ substrate, the PABP1⁴⁵⁶⁻⁴⁶⁶-R⁴⁶⁰-d₆-aDMA internal standard and the PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aDMA reference standard.

LC-MS method for Analysis of Methylated peptides. LC-MS analysis was performed on a Shimadzu LC-20AD system with a Shimadzu Shim-Pack GIST C18 column (3.0 x 150 mm, 3 µm particle size) at 30°C connected to a Shimadzu 8040 triple quadrupole mass spectrometer with an electrospray ionization (ESI) source. The products were eluted with a water–acetonitrile gradient moving from 20% to 92% acetonitrile (0.1% FA) over 6 minutes at a flow rate of 0.5 mL·min⁻¹. The injection volume was 10 µL. The ionization source was operated in positive mode using an interface voltage of 4.5 kV, nebulizing gas at 1.5 L/min, drying gas at 15 L/min and a desolvation line (DL) temperature of 250 °C. The MRM parameter optimization was performed using both the analyte (PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aDMA) and hexadeuterated internal standard (PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-d₆-aDMA). The results of this optimization, which include precursor ion scanning, collision energy, Q1 and Q3 scanning, are summarized in Table 2.

Table 2. Optimized M	RM parameters for the PAE	3P1 analyte and internal standard ^a
----------------------	---------------------------	--

Compounds		Q1 (m/z)	Q3 (m/z)	Q1 PreBias (V)	CE (V)	Q1 PreBias (V)
PABP1-aDMA	analyte	620.85	211.00	-28	-29	-22
			140.00	-28	-47	-25
			282.00	-28	-20	-30
PABP1-d ₆ -aDMA	standard	623.75	210.95	-28	-28	-22
			140.00	-24	-45	-26
			282.00	-28	-19	-29

^aThe interface voltage was set at 4.5 kV for all the compounds; dwell time was 100 ms. Q1: quadrupole 1, Q3: quadrupole 3, m: mass, z: charge, CE: collision energy.

Analytical Method Validation (Linearity, Limits of Detection, accuracy, and precision)

Analysis of the PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aDMA peptide was validated between 16 and 512 nM for within and between run accuracy and precision, the linearity of the calibration curve, the sample recovery, and the limit of detection. Linearity was performed with calibration points consisting of 1, 2, 4, 8, 16, 32, 64, 128, 256,

512 and 1024 nM PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aDMA peptide dissolved in water. Samples for analysis were worked up as described above in the enzymatic reaction assay section and analyzed with the LC-MS/MS method. Area ratios of PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰- aDMA and the hexadeuterated internal standard were assessed and plotted versus concentration. Linearity was assessed visually and by calculation of the coefficient of determination R², which should be >0.98. The limit of detection (LOD) was determined by the samples corresponding to a signal-to-noise (S/N) of 3.

Quality control (QC) samples consist of PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aDMA concentrations of 16, 64, 512 nM and enzymatic reaction buffer (20 mM Tris buffer pH 8, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl₂, 0.1 mg/ml BSA and 1 mM DTT). QC samples for analysis were worked up as described above in the enzymatic reaction assay section and analyzed with the LC-MS/MS method. In order to evaluate the precision and accuracy of the quantification of PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aDMA, concentration values were recalculated for QC using calibration curves. Intra-run accuracy and precision tests were performed using PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aDMA concentrations of 16, 64, 512 nM. Accuracy and precision tests were performed in six-fold per concentration in 1 run and in one-fold per concentration in three separate runs. The acceptance criteria of the accuracy results were 85-115% and of the precision results <15%. The limit of detection was calculated to be 1.55 nM and the method was linear between 8 and 512 nM with a R² of 0.996 (Table 3). The lowest concentration giving a reliable and accurate signal was found to be 16 nM.

ЛА				
[QC] (nM)		R^2		
8-512	0.996			
	Accuracy (%)	Precision CV (%)		
Within run (n=6)				
16	113.7	2.1		
64	87.0	4.7		
512	94.4	5.6		
Between runs (n=3)				

106.2

97.5

91.2

0.1

2.3

4.9

1.55 nM

Table 3. Validation Parameters of the MRM Method for detection of PABP1⁴⁵⁶⁻⁴⁶⁶R⁴⁶⁰-aD-MA

Enzyme Inhibition Assay. The CARM1 inhibition assays were performed using a number of established, commercially available CARM1 inhibitors as well as a series of peptidomimetic inhibitors recently reported our group.²⁸ When using the assay to characterize CARM1 inhibition, the substrates were set at concentrations near their calculated K_M values (12 μ M for the PABP1⁴⁵⁶⁻⁴⁶⁶ peptide and 10 μ M for AdoMet). The inhibitors were tested at 10 different concentrations that were

16

64

512

Limit of detection $(S/N \ge 3)$

selected based on their published IC₅₀ values. For commercially available inhibitors that were not soluble in water, stock solutions were prepared in DMSO and diluted to a final DMSO concentration of <1% in the assay mixture. CARM1 (20 μ L) and inhibitors (10 μ L) were incubated for 15 minutes at room temperature, followed by the addition of a mixture of peptide substrate and AdoMet (10 μ L) to start the reaction. The mixture was incubated for two hours at room temperature and the reaction subsequently quenched by addition of 30 μ L of the reaction mixture to 10 μ L of a 0.1 % formic acid solution (pH 2). After addition of the deuterated internal standard in water (100 nM, 40 μ L) and mixing for 2 minutes, the samples were centrifuged for 5 minutes at 3000 rpm. 60 μ L of the supernatant was transferred to a new 96-well plate and analyzed by LC-MS as described above. Negative controls (no enzyme) and positive controls (no inhibitor) were included in each plate.

Data Analysis. The data obtained from the MRM method included a linearity line with ten different concentrations of reference standard (from 8 to 512 nM) and a fixed concentration of internal standard (100 nM). These data points were subjected to weighted regression $(1/x^2)$. The intercept and slope were used for determination of the measured concentrations.

For quantification of the methylated product, the area ratio of analyte to internal standard was calculated and quantified using the linearity line obtained with the reference standards. The concentrations were then converted to enzyme velocity in nmoles produced/hour/mg CARM1 using equation 1 with the concentration the methylated product in nM, time in minutes, and enzyme concentration in mg/L.

$$v = \frac{[product]^{\frac{60}{t}}}{[E]} \qquad (equation 1)$$

Calculation of V_{max} and K_m was done using Graphpad Prism 6 following nonlinear (Michaelis-Menten) regression analyses using equation 2.

$$v = \frac{V_{max} [S]}{K_m + [S]}$$
 (equation 2)

The k_{cat} was calculated from the V_{max} using equation 3, with V_{max} in nmol/hour/mg enzyme and enzyme concentration in mg/L. To obtain k_{cat} with units of s⁻¹, the maximal velocity (V_{max}) is divided by 3600.

$$k_{cat} = \frac{V_{max}}{[E]}$$
 (equation 3)

The percentage inhibition was plotted as a function of inhibitor concentration and fit using non-linear regression analysis of the sigmoidal dose–response curve



generated using the normalized data and a variable slope following equation 4.

Where Y = percent inhibition, X = the logarithmic concentration of the inhibitors, Hill Slope= slope factor or Hill coefficient. The IC_{50} value was determined by the concentration resulting in half-maximal percent activity. Values reported include the standard errors of the mean (S.E.M., calculated using the symmetrical CI function in Graphpad Prism 6) indicating the precision of the mean values obtained.

References

- 1. D. Cheng, J. Côté, S. Shaaban, M. T. Bedford. The Arginine Methyltransferase CARM1 Regulates the Coupling of Transcription and mRNA Processing. Mol. Cell 2007, 25, 71-83.
- 2. U.-M. Bauer, S. Daujat, S. J. Nielsen, K. Nightingale, T. Kouzarides. Methylation at arginine 17 of histone H3 is linked to gene activation. EMBO reports 2002, 3, 39-44.
- 3. A. Jambhekar, A. Dhall, Y. Shi. Roles and regulation of histone methylation in animal development. Nat. Rev. Mol. Cell Biol. 2019, 20, 625-641.
- 4. S. Wei, C. Li, Z. Yin, J. Wen, H. Meng, L. Xue, J. Wang. Histone methylation in DNA repair and clinical practice: new findings during the past 5-years. J. Cancer 2018, 9, 2072-2081.
- 5. M. T. Bedford, S. G. Clarke. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 2009, 33, 1-13.
- S. C. Larsen, K. B. Sylvestersen, A. Mund, D. Lyon, M. Mullari, M.V. Madsen, J. A. Daniel, L. J. Jensen, M. L. Nielsen. Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells. Sci. Signal 2016, 9, rs9.
- 7. J. Fuhrmann, K. W. Clancy, P. R. Thompson. Chemical Biology of Protein Arginine Modifications in Epigenetic Regulation. Chem. Rev. 2015, 115, 5413-5461.
- Y. R. Kim, B. K. Lee, R. Y. Park, N. T. X. Nguyen, J. A. Bae, D. D. Kwon, C. Jung. Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer 2010, 10, 197.
- 9. R. Elakoum, G. Gauchotte, A. Oussalah, M. P. Wissler, C. Clément-Duchêne, J. M. Vignaud, J. L. Guéant, F. Namour. CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features. Biochimie. 2014, 97, 210-218.
- 10. J. Lin, H. Liu, T. Fukumoto, J. Zundell, Q. Yan, C. H. A. Tang, S. Wu, W. Zhou, D. Guo, S. Karakashev, C. C. A. Hu, K. Sarma, A. V. Kossenkov, R. Zhang. Targeting the IRE1 α /XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nat. Commun. 2021, 12, 5321.
- 11. H. O. Habashy, E. A. Rakha, I. O. Ellis, D. G. Powe. The oestrogen receptor

coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. Breast Cancer Res. Treat. 2013, 140, 307-316.

- Krijt, A. Dutá, V. Kožich. Determination of S-Adenosylmethionine and S-Adenosylhomocysteine by LC–MS/MS and evaluation of their stability in mice tissues. J. Chromatogr. B 2009, 877, 2061-2066.
- 13.K. Hsiao, H. Zegzouti, S. A. Goueli. Methyltransferase-Glo: a universal, bioluminescent and homogenous assay for monitoring all classes of methyltransferases. Epigenomics 2016, 8, 321-339.
- 14.G. Dong, A. Yasgar, D. L. Peterson, A. Zakharov, D. Talley, K. C. C. Cheng, A. Jadhav, A. Simeonov, R. Huang. Optimization of High-Throughput Methyltransferase Assays for the Discovery of Small Molecule Inhibitors. ACS Comb. Sci. 2020, 22, 422-432.
- L. Wang, P. Charoensuksai, N. J. Wats0on, X. Wang, Z. Zhao, C. G. Coriano, L. R. Kerr, W. Xu. CARM1 automethylation is controlled at the level of alternative splicing. Nucleic Acids Res. 2013, 41, 6870-6880.
- 16. H. Hu, K. Qian, M. C. Ho, Y. G. Zheng. Small Molecule Inhibitors of Protein Arginine Methyltransferases. Expert Opin Investig Drugs 2016, 25, 335-358.
- D. Cheng, N. Yadav, R. W. King, M. S. Swanson, E. J. Weinstein, M. T. Bedford. Small Molecule Regulators of Protein Arginine Methyltransferases*. J. Biol. Chem. 2004, 279, 23892-23899.
- 18. V. Lange, P. Picotti, B. Domon, R. Aebersold. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
- D. Chen, H. Ma, H. Hong, S. S. Koh, S. M. Huang, B. T. Schurter, D. W. Aswad, M. R. Stallcup. Regulation of transcription by a protein methyltransferase. Science 1999, 284, 2174-2177.
- 20. A. Di Lorenzo, M. T. Bedford. Histone arginine methylation. FEBS Lett. 2011, 585, 2024-2031.
- S. L. Jacques, K. P. Aquino, J. Gureasko, P. A. Boriack-Sjodin, M. Porter Scott, R. A. Copeland, T. V. Riera. CARM1 Preferentially Methylates H3R17 over H3R26 through a Random Kinetic Mechanism. Biochemistry 2016, 55, 1635-1644.
- A. E. Drew, O. Moradei, S. L. Jacques, N. Rioux, A. P. Boriack-Sjodin, C. Allain, M. P. Scott, L. Jin, A. Raimondi, J. L. Handler, H. M. Ott, R. G. Kruger, M. T. McCabe, C. Sneeringer, T. Riera, G. Shapiro, N. J. Waters, L. H. Mitchell, K. W. Duncan, M. P. Moyer, R. A. Copeland, J. Smith, R. Chesworth, S. A. Ribich. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Sci. Rep. 2017, 7, 17993.
- 23.G. Blobel. A protein of molecular weight 78,000 bound to the polyadenylate region of eukaryotic messenger RNAs. Proc Natl Acad Sci U S A 1973, 70, 924-928.
- 24. J. Lee, M. T. Bedford. PABP1 identified as an arginine methyltransferase substrate using high-density protein arrays. EMBO Rep 2002, 3, 268-273.

- 25. Martin, N. I., and Liskamp, R. M. J. Preparation of NG-Substituted I-Arginine Analogues Suitable for Solid Phase Peptide Synthesis. J. Org. Chem. 2008, 73, 7849-7851.
- 26. M. J. van Haren, N. Marechal, N. Troffer-Charlier, A. Cianciulli, G. Sbardella, J. Cavarelli, N. I. Martin. Transition state mimics are valuable mechanistic probes for structural studies with the arginine methyltransferase CARM1. Proc Natl Acad Sci U S A 2017, 114, 3625.
- 27. R. Wang, Y. Wang, T. C. Edrington, Z. Liu, T. C. Lee, A. Silvanovich, H. S. Moon, Z. L. Liu, B. Li. Presence of small resistant peptides from new in vitro digestion assays detected by liquid chromatography tandem mass spectrometry: An implication of allergenicity prediction of novel proteins? PloS one 2020, 15, e0233745-e0233745.
- 28. Y. Zhang, N. Marechal, M. J. van Haren, N. Troffer-Charlier, V. Cura, J. Cavarelli, N. I. Martin. Structural Studies Provide New Insights into the Role of Lysine Acetylation on Substrate Recognition by CARM1 and Inform the Design of Potent Peptidomimetic Inhibitors. ChemBioChem 2021, 22, 3469-3476.
- 29. Y. Shen, M. M. Szewczyk, M. S. Eram, D. Smil, H. Kaniskan, R. F. de Freitas, G. Senisterra, F. Li, M. Schapira, P. J. Brown, C. H. Arrowsmith, D. Barsyte-Lovejoy, J. Liu, M. Vedadi, J. Jin. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. J. Med. Chem. 2016, 59, 9124-9139.
- 30. M. S. Eram, Y. Shen, M. Szewczyk, H. Wu, G. Senisterra, F. Li, K. V. Butler, H. Kaniskan, B. A. Speed, C. Dela Seña, A. Dong, H. Zeng, M. Schapira, P. J. Brown, C. H. Arrowsmith, D. Barsyte-Lovejoy, J. Liu, M. Vedadi, J. Jin. A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. ACS Chem Biol 2016, 11, 772-781.
- 31. K. Nakayama, M. M. Szewczyk, C. Dela Sena, H. Wu, A. Dong, H. Zeng, F. Li, R. F. de Freitas, M. S. Eram, M. Schapira, Y. Baba, M. Kunitomo, D. R. Cary, M. Tawada, M., A. Ohashi, Y. Imaeda, K. S. Saikatendu, C. E. Grimshaw, M. Vedadi, C. H. Arrowsmith, D. Barsyte-Lovejoy, A. Kiba, D. Tomita, P. J. Brown. TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget 2018, 9, 18480-18493.
- 32. V. A. Shatrov, M. Ameyar, Z. Cai, A. Bettaieb, S. Chouaib. Methyltransferase inhibitor S-adenosyl-L-homocysteine sensitizes human breast carcinoma MCF7 cells and related TNF-resistant derivatives to TNF-mediated cytotoxicity via the ceramide-independent pathway. Eur Cytokine Netw 1999, 10, 247-252.
- 33. W. W. Yue, M. Hassler, S. M. Roe, V. Thompson-Vale, L. H. Pearl. Insights into histone code syntax from structural and biochemical studies of CARM1 methyltransferase. EMBO J. 2007, 26, 4402-4412.